{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:22:26Z","timestamp":1774084946181,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145409","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T14:12:02Z","timestamp":1452521522000},"page":"e0145409","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies"],"prefix":"10.1371","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01482390","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01482403","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Scalori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Le Pogam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"N\u00e1jera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Thommes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"J Hepatol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Hanafiah K Mohd","year":"2013","journal-title":"Hepatology"},{"key":"ref3","unstructured":"AASLD\/IDSA\/IAS\u2013USA. Recommendations for testing, managing, and treating hepatitis C. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\" xlink:type=\"simple\">http:\/\/www.hcvguidelines.org<\/ext-link> [Accessed May 14, 2015]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\" xlink:type=\"simple\">http:\/\/www.hcvguidelines.org<\/ext-link>."},{"key":"ref4","article-title":"EASL recommendations on treatment of hepatitis C 2015","year":"2015","journal-title":"J Hepatol"},{"issue":"24","key":"ref5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"AJ van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"18","key":"ref6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","article-title":"Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population","volume":"312","author":"AJ van der Meer","year":"2014","journal-title":"JAMA"},{"key":"ref7","unstructured":"Merck and Co. Whitehouse Station, NJ, USA. Victrelis Prescribing Information. 2013."},{"key":"ref8","unstructured":"Vertex Pharmaceuticals Inc. Cambridge, MA, USA. Incivek prescribing Information. 2013."},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"ref10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"ref11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"ref12","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2013.12.013","article-title":"Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon\/ribavirin, including prior null response","volume":"60","author":"JM Vierling","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","article-title":"Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting","volume":"8","author":"B Maasoumy","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2014.06.005","article-title":"Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program","volume":"61","author":"M Colombo","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"C Hezode","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"AS Lok","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2014.09.013","article-title":"Randomized study of danoprevir\/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon\/ribavirin","volume":"62","author":"JJ Feld","year":"2015","journal-title":"J Hepatol"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients","volume":"202","author":"S Le Pogam","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/AAC.01035-12","article-title":"Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3\/4 protease inhibitor danoprevir","volume":"56","author":"S Le Pogam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"X Tong","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.26275","article-title":"JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a\/ribavirin for 24 weeks in treatment-naive HCV genotype 1\/4 patients","volume":"58","author":"PJ Pockros","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep.26274","article-title":"PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a\/ribavirin therapy in treatment-naive HCV genotype 1\/4 patients","volume":"58","author":"H Wedemeyer","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl","key":"ref24","first-page":"741A","article-title":"Interferon-free regimen containing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine in HCV genotype 1 treatment-naive patients: interim results from the ANNAPURNA study","volume":"58","author":"DM Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12588","article-title":"Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study","volume":"35","author":"EJ Gane","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","article-title":"Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial","volume":"15","author":"KR Reddy","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1128\/AAC.00399-13","article-title":"Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations","volume":"57","author":"G Kalkeri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/infdis\/jit338","article-title":"Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3\/4A protease","volume":"208","author":"Z Zhu","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","article-title":"Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus","volume":"18","author":"K Morikawa","year":"2011","journal-title":"J Viral Hepat"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"KE Sherman","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"S Susser","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"JC Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"e1003772","DOI":"10.1371\/journal.pcbi.1003772","article-title":"Modeling viral evolutionary dynamics after telaprevir-based treatment","volume":"10","author":"EL Haseltine","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2015.03.018","article-title":"A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants","volume":"219","author":"CK Ho","year":"2015","journal-title":"J Virol Methods"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.01515-13","article-title":"Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders","volume":"58","author":"EJ Gane","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"MG Ghany","year":"2011","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:54:54Z","timestamp":1588971294000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145409"}},"subtitle":[],"editor":[{"given":"Chien-Wei","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145409","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726067980.793513526","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}